This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

The Real Winners of Drug Experimentation

The Wall Street Angle

"Sigma-Aldrich's substantial pricing power and topnotch sales and distribution model have helped the company earn steady profits for more than a decade," says analyst Ben Johnson of the independent research firm Morningstar, in a recent report. "[Its] winning streak will continue for years to come."

He notes that the company sells a whopping 145,000 products for medical, scientific and industrial uses to commercial, academic and university clients. No customer accounts for more than 3% of sales. Johnson's greatest concerns would be a "softness" in clients' R&D spending due to cutbacks in government funding and the currency risk for a company that gets more than half of its revenue from foreign markets.

He gives Sigma-Aldrich a two-star rating -- five stars represents the best buying opportunity -- indicating its recent price in the high $50s has outrun his fair value estimate of $51 a share. Among sell-side analysts, four have buy ratings while five are neutral, says Thomson First Call.

Johnson adds that Sigma-Aldrich has a "rock solid balance sheet" thanks to disciplined management. "Despite a large cash balance, the company has refrained from overpaying for acquisitions in a pricey market," Johnson says.

Aggressive expansion tripped up Invitrogen for a few years, and the company is still paying on Wall Street where there are eight hold ratings vs. four buy recommendations, says Thomson First Call. However, Invitrogen posted a 30% stock gain for the 12 months ended March 20 and a 160% gain for the past five years.

"Only two years ago, the words 'predictable' and 'consistent' were the antithesis of Invitrogen's business and performance," says Ross Muken of Deutsche Bank, in a March 18 research report. Invitrogen had been plagued with "numerous mistakes and miscues [including] failed acquisitions [and] technology missteps," says Muken, who raised his rating to buy from hold in February.

Invitrogen's "current business is the envy of many managers," says Muken, who doesn't own shares. His firm says it does -- and seeks to do -- business with companies mentioned in research reports.

Morningstar analyst Jeff Viksjo says the stock is still too expensive, even though the price is down from the high $90s in December to the low $80s in March. He gives Invitrogen two stars and he pegs a fair value at $68 a share. In February, he told subscribers that even though Invitrogen has a "wide collection of top research brands," it still "must make its operations more efficient to create value for shareholders."

Because Invitrogen competes with many companies selling similar products, there is "little opportunity to raise prices," he says. "There are almost no barriers to entry in the industry, and start-up firms routinely develop new technologies that challenge existing ones."
2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ABI $22.98 1.01%
SIAL $139.76 -0.04%
MIL $2.18 0.00%
QGEN $21.05 0.00%
TMO $123.18 0.00%


Chart of I:DJI
DOW 16,204.97 -211.61 -1.29%
S&P 500 1,880.05 -35.40 -1.85%
NASDAQ 4,363.1440 -146.4150 -3.25%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs